Drug Database
PO

polyvalent human immunoglobulin (liquid) (Clairyg)

✓ Approved

LFB · Polyclonal Antibodies · Polyclonal Antibodies

What is polyvalent human immunoglobulin (liquid)?

polyvalent human immunoglobulin (liquid) is a polyclonal antibodies developed by LFB. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesClairyg
CompanyLFB
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, LFB

Therapeutic Indications

polyvalent human immunoglobulin (liquid) is developed for 7 unique indications across 5 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersGuillain-Barre syndrome✓ Approved
Skin and subcutaneous tissue disordersPurpura✓ Approved
Congenital, familial and genetic disordersWiskott-Aldrich syndrome✓ Approved
Immune system disordersSelective IgG subclass deficiency✓ Approved
Congenital, familial and genetic disordersBruton's agammaglobulinaemia✓ Approved

+2 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedMolecules (Basel, Switzerland)2026-10-16

Essential Oil-Containing Mouthrinses for Plaque and Gingivitis Control: Formulation Chemistry, Human Salivary Biomarkers, Mechanistic Evidence, and Research Priorities.

Sytykiewicz Hubert H

Selected essential oil (EO)-containing mouthrinses improve plaque and gingivitis control when used alongside mechanical oral hygiene, but their molecular effects in human saliva remain poorly defined. This narrative review integrates formulation chemistry, oral exposure, human salivary evidence, and mechanistic studies. Three studies identified in this review evaluated salivary immunoglobulin A, immunoglobulin G, or interleukin-1β. Differences in populations, co-interventions, sampling, and analytical methods limit comparison and do not establish reproducible modulation of a single biomarker. Other human studies assessed salivary flow, pH, proteomic responses, microbial counts, nitrate reduction, and oral biofilms. Mechanistic evidence largely derives from isolated constituents in cellular, animal, or computational models. A study of a complete zinc-containing formulation in human oral cells provides formulation-level evidence, but neither this study nor the constituent literature establishes target engagement after mouthrinsing in humans. Future trials should connect chemically characterized formulations and measured oral exposure with target-specific assays, validated salivary endpoints, microbial function, clinical outcomes, and safety. Current evidence supports selected formulations for plaque and gingivitis control; it does not establish an EO class effect or a validated salivary mechanism of clinical benefit.

PMID 42883182
Read full article →
PubMedNeurology and therapy2026-10-16

Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Kuatov Batyrkhan B, Weng Shicheng S, Hubsch Alphonse A, Undreiner Laurence L et al.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, inflammatory peripheral nervous system disorder. Intravenous immunoglobulin (IVIG) has been the standard maintenance therapy, but since 2018, Immune Globulin Subcutaneous (Human), 20% liquid (IgPro20), a subcutaneous immunoglobulin (SCIG) therapy, has offered an alternative, demonstrating benefit in maintaining CIDP improvement and remission. This study aimed to evaluate real-world healthcare resource utilization (HCRU), adherence, and persistence following IgPro20 initiation in patients with CIDP, given limited real-world evidence on these SCIG-related outcomes. This observational, descriptive study used Optum's de-identified Clinformatics® Data Mart Database (Optum® CDM) data to examine adults with CIDP initiating IgPro20 (index date). Adult patients with ≥ 2 CIDP diagnosis claims at least 14 days apart and ≥ 6 months of enrollment pre- and post-index between January 1, 2014 and December 31, 2024 were included. Those on other SCIG products were excluded. Patients with CIDP initiating IgPro20 (N = 207) were 53.6% male, with a median age of 60.00 and few comorbidities. Acute care utilization was low at baseline and decreased further following IgPro20 initiation, with inpatient and emergency department visits per patient per year (PPPY) decreasing from 0.52 to 0.42 and from 1.00 to 0.85, respectively. Overall, outpatient (OP) visits increased from 60.62 PPPY pre-initiation to 92.61 PPPY in month 1 post-initiation, driven by visits for CIDP-related home administration, notably for nursing/home-care for self-administration training. OP visits subsequently declined to 67.43 PPPY by month 6 (n = 141). Most patients (69.1%) were highly adherent, and 63.8% remained persistent at 6 months. Patients on IgPro20 administration demonstrated therapy adherence and decreased utilization of resource-intensive settings. While initial increases in outpatient and home care visits likely reflect training for at-home therapy, other outpatient healthcare utilization decreased. High persistence and adherence indicate sustained, uninterrupted therapy.

PMID 42881325
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Systematic Profiling Reveals Propensity of Human Ion Channels for Liquid-Liquid Phase Separation.

Li Jiamin J, Yao Yijing Y, Yu Ran R, Cui Siyu S et al.

Liquid-liquid phase separation (LLPS), a fundamental biophysical process driven by multivalent weak interactions, regulates diverse cellular physiological functions. Ion channels are critical transmembrane protein complexes governing electrophysiological signaling, yet their phase separation characteristics remain largely uncharacterized. Here, we systematically assessed the phase-separation propensity of 140 human ion-channel proteins from the PhaSePred database, and 69 human ion channel proteins were predicted to have a high propensity for LLPS (prediction score ≥ 0.5). Based on the self-assembling phase-separating (PS-Self) and partner-dependent phase-separating (PS-Part) scores of the proteins, we classified ion channel proteins with a ratio (PS-Self/PS-Part) > 1 into the PS-Self group and those with a ratio < 1 into the PS-Part group. Ultimately, 37 proteins were predicted to tend toward PS-Self, and 32 to tend toward PS-Part. Moreover, PS-Self candidates exhibited higher hydropathy and pi-pi contact scores, whereas predicted PS-Part candidates showed higher IDR, LCR, and phosphorylation-associated scores. Experimental analyses identified intracellular regions of CaV1.2, CaV1.3, NaV1.5, and KCa2.2 that formed dynamic condensate-like assemblies when expressed in HeLa cells. Our findings elucidate the phase separation classification and core structural domains mediating LLPS in key ion channels and providing a molecular basis for understanding the pathophysiological roles of ion channel phase separation in cardiac and neurological disorders and may inform the development of phase-separation-targeted diagnostic and therapeutic strategies.

PMID 42883847
Read full article →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

High Prevalence of Oxford MEST-C Lesions in Immunoglobulin A Nephropathy of Kidney Allografts: A Single-Center Study from Viet Nam.

Thai Kinh Luan KL, La Ngoc Thu Nguyen NTN, Hoang Tien Dat TD, Duong Nguyen Xuong NX et al.

We evaluated the clinical characteristics, Oxford 2016 histopathology features, and short-term outcomes of Immunoglobulin A nephropathy in kidney transplant recipients at Cho Ray Hospital, Ho Chi Minh City, Viet Nam. This retrospective, descriptive study included kidney transplant recipients with biopsy -proven immunoglobulin A nephropathy in kidney allografts identified in 2022. We analyzed patient death with a functioning graft as a competing event and not classified as graft failure. Immunoglobulin A nephropathy was present in 27.1 % (19/70 ) of allograft biopsies. Most recipients were male (73.7 %) and received grafts from living related donors (17 /19, 89.4 % ). The mean time from transplant to immunoglobulin A nephropathy diagnosis was 5.2 years. Median follow -up after biopsy was 48 weeks. Three components of the Oxford MEST -C were frequently observed, that is, mesangial hypercellularity M1 (73.7 % ), segmental glomerulosclerosis S1 (78.9 % ), and cellular /fibrocellular crescents C1 (26.3 % ). At the end of follow -up, 68.4 % of patients maintained graft function, 15.8 % required hemodialysis, and 10.5 % died from nonrenal causes with functioning grafts. Immunoglobulin A nephropathy was frequently observed in our patient cohort; however, the inability to distinguish recurrent disease from de novo disease fundamentally limited interpretation of the histopathology patterns. Moreover, given the short -term and multifactorial nature of the outcomes, together with the limitations of the Oxford MEST -C in the allograft setting, the independent prognostic significance of these lesions remains uncertain and requires further validation through larger prospective studies.

PMID 42885704
Read full article →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

Hepatitis B Virus Recurrence After Liver Transplant for Hepatitis B Virus-Related Liver Disease: A Retrospective Analysis of Hepatitis B Immunoglobulin Discontinuation.

Aktuna Hakan H, Daniş Nilay N, Döngelli Hüseyin H, Bacakoğlu Aylin A et al.

Hepatitis B virus recurrence after liver transplant remains a clinically relevant issue, but the optimal duration and safety of hepatitis B immunoglobulin therapy, particularly its discontinuation, remain unclear. Here, we evaluated the incidence and risk factors of posttransplant hepatitis B virus recurrence and assessed outcomes following elective discontinuation of hepatitis B immunoglobulin in a real-world cohort. We conducted a retrospective single-center cohort study of consecutive adult patients who underwent liver transplant for hepatitis B virus-related liver disease between 1997 and 2023. Hepatitis B virus recurrence was defined as the reappearance of hepatitis B surface antigen and/or detectable hepatitis B virus DNA. We used Cox proportional hazards models to identify factors associated with recurrence and overall survival. We conducted a predefined subgroup analysis to evaluate patients who underwent elective discontinuation of hepatitis B immunoglobulin during antiviral therapy. Among 254 liver transplant recipients, 39 (15.4% ) developed posttransplant hepatitis B virus recurrence. In multivariable analysis, pretransplant hepatitis B virus DNA levels >5 log10 copies/mL (hazard ratio 3.68; 95% CI, 1.82-7.46) and hepato-cellular carcinoma at transplant (hazard ratio 2.38; 95% CI, 1.22-4.65) were independently associated with recurrence, whereas hepatitis D virus coinfection was inversely associated (hazard ratio 0.18; 95% CI, 0.08-0.43). Elective hepatitis B immunoglobulin discontinuation was not associated with increased hepatitis B virus recurrence and was primarily performed in clinically selected low-risk patients. Posttransplant hepatitis B virus recurrence was associated with reduced overall survival. In this long-term, real-world cohort, posttransplant hepatitis B virus recurrence was mainly driven by the pretransplant viral burden and oncological factors. Elective hepatitis B immunoglobulin discontinuation in carefully selected patients was not associated with increased recurrence, likely reflecting the underlying risk stratification rather than a causal protective effect. These findings support the use of individualized risk-based hepatitis B immunoglobulin strategies after liver transplant.

PMID 42885707
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-16

Thickness-Gradient Liquid Metal Connectors for Seamless Electrophysiological Sensors.

Kim Jinyoung J, Lee Jaejun J, Tabor Christopher E CE, Tsukruk Vladimir V VV

High-fidelity electrophysiological monitoring requires wearable bioelectronic devices with mechanical properties closely matched to human skin. However, current approaches focus primarily on electrode design and performance, while overlooking mechanical compliance and interfacial continuity with complex and dynamic human skin. Mechanical mismatches across electrodes, connectors, and interconnects often lead to interfacial noise, motion artifacts, and electrical instability. In order to overcome these critical issues, we introduce a thickness-gradient liquid metal (LM)/SEBS connector that enables seamless interfacial integration with skin, electrode, and interconnector interfaces through gradual mechanical compliance matching and manually activated metal network formation. The activated LM forms continuous and robust conductive networks, maintaining electrical stability under large tensile strain (∼1100%) and for repeatable deformation cycles. Skin-mimetic conformal integration suggested here suppresses interfacial void formation and stress concentration and thereby preserves stable electrical pathways under dynamic skin deformation. As a result, the proposed system delivers markedly improved signal amplitude and signal-to-noise ratio, along with substantially lower noise, relative to conventional connector platforms. By systematically aligning mechanical compliance across sensor components, this mechanically adaptive design preserves seamless electrical pathways and minimizes motion-induced artifacts under dynamic conditions, providing a robust platform for reliable electrophysiological monitoring in long-lasting wearable bioelectronics.

PMID 42886164
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about polyvalent human immunoglobulin (liquid)